Also known as: Isturisa
Isturisa (osilodrostat) is an oral cortisol synthesis inhibitor approved in the U.S. for adults with Cushing's disease when pituitary surgery is not possible or has not been curative. It is typically initiated twice daily and titrated based on cortisol response and clinical status. Initial U.S. approval was granted in 2020.
A federal appeals court affirmed a ruling finding no infringement of two Korlym-related patents by Teva's proposed generic. The decision removes a major legal barrier for generic competition.
Italian pharmaceutical company Recordati reported 2025 revenues of €2.6 billion and adjusted net profit of €651.1 million, with rare disease therapies driving 29.7% growth. The company projects 2026 core earnings of €995 million to €1.03 billion, anticipating continued momentum in its specialized rare disease treatments.
Belite Bio announced preliminary Q4 2025 results and plans to submit an NDA for tinlarebant in Q2 2026 following positive Phase 3 trial results. BioArctic reported record financial results with operating profit exceeding SEK 1.2 billion for 2025. Recordati delivered strong preliminary full-year 2025 results despite FX headwinds.
